Expression of miR-23a and miR-135 and tumor markers in gastric cancer patients and the significance in diagnosis

Yin,Likui; Xu,Guangxiao; Zhu,Yuntao; Wang,Yongqiang

doi:10.3892/ol.2019.10943

Expression of miR-23a and miR-135 and tumor markers in gastric cancer patients and the significance in diagnosis

Authors:
- Likui Yin
- Guangxiao Xu
- Yuntao Zhu
- Yongqiang Wang
View Affiliations

Affiliations: Clinical Laboratory, Dongying People's Hospital, Dongying, Shandong 257091, P.R. China, Department of Surgery, Dongying People's Hospital, Dongying, Shandong 257091, P.R. China, Clinical Laboratory, Jinxiang County People's Hospital, Jinxiang, Shandong 272200, P.R. China, Department of Urology Surgery, Yantai Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China
Published online on: October 1, 2019 https://doi.org/10.3892/ol.2019.10943
Pages: 5853-5858
Copyright: © Yin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Correlation between the expression of miR-23a and miR-135 and tumor markers in gastric cancer patients and their significance in diagnosis was investigated. A total of 78 patients with gastric cancer admitted to Dongying People's Hospital from July 2015 to June 2017 were enrolled, and 80 healthy patients were selected as the control group during the same period. The expression levels of miR-23a and miR-135 in the serum of the two groups were detected by RT-qPCR, and the expression levels of tumor markers CEA and carbohydrate antigen 199 (CA199) were detected by ELISA. The receiver operating characteristic curve and area under the curve (AUC) were used to evaluate the diagnostic efficacy of miR-23a and miR-135 as diagnostic indicators. There was no significant difference between the observation and the control group (P>0.05). The expression levels of miR-23a and miR-135 in the observation group were significantly higher than those in the control group (P<0.05). The expression levels of CEA and CA199 in serum of patients in the observation group were significantly higher than those in the control group (P<0.05). Pearson's correlation test showed that the expression levels of miR-23a and miR-135 were positively correlated with CEA and CA199 (P<0.05). The specificity, sensitivity and AUC of miR-23a in the diagnosis of gastric cancer were 67.95, 87.50 and 0.805%, respectively. The specificity, sensitivity and AUC of miR-135 in the diagnosis of gastric cancer were 73.08, 82.50 and 0.824%, respectively. Both could be used in the diagnosis of gastric cancer. In conclusion, miR-23a and miR-135 are highly expressed in gastric cancer patients and positively correlated with tumor markers, which can be used in diagnosis for gastric cancer.

View Figures

View References

1	Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R and Polkowski WP: Gastric cancer: Epidemiology, prevention, classification, and treatment. Cancer Manag Res. 10:239–248. 2018. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Shen L, Li J, Xu J, Pan H, Dai G, Qin S, Wang L, Wang J, Yang Z, Shu Y, et al: Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: Randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 18:168–176. 2015. View Article : Google Scholar : PubMed/NCBI
4	Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, Zhang L, Tang J, Chen J, Wei K, et al: Cancer survival in China, 2003–2005: A population-based study. Int J Cancer. 136:1921–1930. 2015. View Article : Google Scholar : PubMed/NCBI
5	Buckland G, Travier N, Huerta JM, Bueno-de-Mesquita HB, Siersema PD, Skeie G, Weiderpass E, Engeset D, Ericson U, Ohlsson B, et al: Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study. Int J Cancer. 137:598–606. 2015. View Article : Google Scholar : PubMed/NCBI
6	Massarrat S and Stolte M: Development of gastric cancer and its prevention. Arch Iran Med. 17:514–520. 2014.PubMed/NCBI
7	Rao SA, Santosh V and Somasundaram K: Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol. 23:1404–1417. 2010. View Article : Google Scholar : PubMed/NCBI
8	Zhu XL, Ren LF, Wang HP, Bai ZT, Zhang L, Meng WB, Zhu KX, Ding FH, Miao L, Yan J, et al: Plasma microRNAs as potential new biomarkers for early detection of early gastric cancer. World J Gastroenterol. 25:1580–1591. 2019. View Article : Google Scholar : PubMed/NCBI
9	Li L, Zhu X, Shou T, Yang L, Cheng X, Wang J, Deng L and Zheng Y: MicroRNA-28 promotes cell proliferation and invasion in gastric cancer via the PTEN/PI3K/AKT signalling pathway. Mol Med Rep. 17:4003–4010. 2018.PubMed/NCBI
10	Peng QP, Du DB, Ming Q, Hu F, Wu ZB and Qiu S: MicroRNA 494 increases chemosensitivity to doxorubicin in gastric cancer cells by targeting phosphodiesterases 4D. Cell Mol Biol. 64:62–66. 2018. View Article : Google Scholar : PubMed/NCBI
11	Qu WQ, Liu L and Yu Z: Clinical value of microRNA-23a upregulation in non-small cell lung cancer. Int J Clin Exp Med. 8:13598–13603. 2015.PubMed/NCBI
12	Zhang XW, Liu N, Chen S, Wang Y, Zhang ZX, Sun YY, Qiu GB and Fu WN: High microRNA-23a expression in laryngeal squamous cell carcinoma is associated with poor patient prognosis. Diagn Pathol. 10:222015. View Article : Google Scholar : PubMed/NCBI
13	Wang N and Zhang T: Downregulation of MicroRNA-135 promotes sensitivity of non-small cell lung cancer to Gefitinib by targeting TRIM16. Oncol Res. 26:1005–1014. 2018. View Article : Google Scholar : PubMed/NCBI
14	Virgilio E, Proietti A, D'Urso R, Cardelli P, Giarnieri E, Montagnini M, Giovagnoli MR, Mercantini P, Balducci G and Cavallini M: Measuring intragastric tumor markers in gastric cancer patients: A systematic literature review on significance and reliability. Anticancer Res. 37:2817–2821. 2017.PubMed/NCBI
15	Xiao S, Feng F, Sun L, Cai L, Liu Z, Liu S, Fan D and Zhang H: Blood type AB predicts promising prognosis in gastric cancer patients with positive preoperative serum CEA. Medicine (Baltimore). 96:e84962017. View Article : Google Scholar : PubMed/NCBI
16	Tu H, Sun L, Dong X, Gong Y, Xu Q, Jing J, Bostick RM, Wu X and Yuan Y: A serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: A multi-phase study. Am J Gastroenterol. 112:704–715. 2017. View Article : Google Scholar : PubMed/NCBI
17	Wang L, Wang X H, Kou H J, et al: Comparing single oral contrast-enhanced ultrasonography and double contrast-enhanced ultrasonography in the preoperative Borrmann classification of advanced gastric cancer. Oncotarget. 9:87162018.PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Okines A, Verheij M, Allum W, Cunningham D and Cervantes A; ESMO Guidelines Working Group, : Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21 (Suppl 5):v50–v54. 2010. View Article : Google Scholar : PubMed/NCBI
20	Deng G, Qu J, Zhai S, Shi Y and Wang X: Effect of neoadjuvant chemotherapy on nutritional status of locally advanced gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 21:331–335. 2018.(In Chinese). PubMed/NCBI
21	Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, et al: Management of gastric cancer in Asia: Resource-stratified guidelines. Lancet Oncol. 14:e535–e547. 2013. View Article : Google Scholar : PubMed/NCBI
22	Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H and Ajani JA: Proteomics approach to identify biomarkers for upper gastrointestinal cancer. Expert Rev Proteomics. 13:1041–1053. 2016. View Article : Google Scholar : PubMed/NCBI
23	Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L and Yu H: High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat. 117:131–140. 2009. View Article : Google Scholar : PubMed/NCBI
24	Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y, Kong R, Luo Y, Shi Y, Wang K, et al: miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun. 433:207–212. 2013. View Article : Google Scholar : PubMed/NCBI
25	Baranwal S and Alahari SK: miRNA control of tumor cell invasion and metastasis. Int J Cancer. 126:1283–1290. 2010.PubMed/NCBI
26	Rupaimoole R, Calin GA, Lopez-Berestein G and Sood AK: miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
27	Zhu LH, Liu T, Tang H, Tian RQ, Su C, Liu M and Li X: MicroRNA-23a promotes the growth of gastric adenocarcinoma cell line MGC803 and downregulates interleukin-6 receptor. FEBS J. 277:3726–3734. 2010. View Article : Google Scholar : PubMed/NCBI
28	Zhou W, Li X, Liu F, Xiao Z, He M, Shen S and Liu S: MiR-135a promotes growth and invasion of colorectal cancer via metastasis suppressor 1 in vitro. Acta Biochim Biophys Sin (Shanghai). 44:838–846. 2012. View Article : Google Scholar : PubMed/NCBI
29	Golubovskaya VM, Sumbler B, Ho B, Yemma M and Cance WG: MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells. Anticancer Agents Med Chem. 14:18–28. 2014. View Article : Google Scholar : PubMed/NCBI